Drotaverine, tablets 40 mg, 100 pcs.

Pharmacological action – myotropic, antispasmodic, vasodilator.

In terms of chemical structure and pharmacological properties it is similar to papaverine, but its effect is stronger and more prolonged. It reduces the entry of calcium ions into smooth muscle cells (inhibits phosphodiesterase, leads to the accumulation of intracellular cAMP).

Limits smooth muscle tone of internal organs and intestinal peristalsis, dilates blood vessels. It does not affect the autonomic nervous system; it does not penetrate into the central nervous system.

The direct effect on the smooth muscles allows it to be used as an antispasmodic when drugs from the group of M-cholinoblockers are contraindicated (closed-angle glaucoma, prostatic hyperplasia).

Pharmacokinetics

In oral administration the absorption is high, half-absorption period is 12 minutes. Bioavailability – 100%. It is evenly distributed in the tissues, penetrates into the smooth muscle cells.

The time to reach maximum concentration in the blood is 2 hours. Binding with plasma proteins is 95-98%. It is mainly excreted by the kidneys, to a lesser extent – with the bile.

It does not penetrate through the blood-brain barrier.

Indications

Colic, Headache, Gallstone disease, Painful menstruation (algodysmenorrhea), Gastroduodenitis, cholecystitis, urolithiasis, Gastritis, Colitis, Enteritis, Pain, Gall colic, Renal colic, Threatened miscarriage, Bloating, Stomach and duodenal ulcer

.

Active ingredient

Drotaverine

Composition

1 tablet contains:

the active ingredient:

40 mg drotaverine hydrochloride.

Auxiliary substances:

Potato starch,

lactose,

polyvinyl-pyrrolidone (povidone),

talk,

magnesium stearate

How to take, the dosage

Adults are prescribed orally in 40-80 mg (1-2 tablets) 2-3 times a day.

In children under 6 years of age a single dose of 10-20 mg (1/4-1/2 tablets), from 6 to 12 years – 20 mg (1/2 tablet) 1-2 times a day.

Interaction

In concomitant use may weaken the anti-Parkinsonian effect of levodopa.

It potentiates the effect of papaverine, bendazole and other antispasmodics (including M-cholinoblockers), reduction of blood pressure caused by tricyclic antidepressants, quinidine and procainamide.

Limits the antispasmodic activity of morphine.

Phenobarbital increases the spasmolytic effect of drotaverine hydrochloride.

.

Special Instructions

At the time of treatment it is necessary to refrain from driving and engaging in potentially dangerous activities that require high concentration and quick psychomotor reactions.

.

Contraindications

• high sensitivity to the components of the drug,
• explicit hepatic, renal, cardiac failure;
• trioventricular block of degree II-III,
• cardiogenic shock,
• arterial hypotension.

With caution – marked atherosclerosis of coronary arteries, prostatic hyperplasia, closed-angle glaucoma, pregnancy and lactation.

.

Side effects

Central nervous system: infrequent – dizziness.

Cardiovascular system: infrequent – palpitations, decreased blood pressure.

Perception of fever and sweating.

Allergic skin reactions.

.

Overdose

In high doses it disrupts atrial-ventricular conduction, reduces excitability of the heart muscle, can cause cardiac arrest and paralysis of the respiratory center.

Pregnancy use

The drug is used with caution during pregnancy and lactation (breast-feeding).

It is contraindicated in children under 2 years of age.

.

Similarities

No-shpa, Drotaverine, Spasmonet, Drotaverine-Teva